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HIF-1α is required for hematopoietic stem cell mobilization
and 4-prolyl hydroxylase inhibitors enhance mobilization by
stabilizing HIF-1α
CE Forristal1, B Nowlan1, RN Jacobsen1,2, V Barbier1, G Walkinshaw3, CR Walkley4, IG Winkler1 and JP Levesque1,2
Many patients with hematological neoplasms fail to mobilize sufficient numbers of hematopoietic stem cells (HSCs) in response to
granulocyte colony-stimulating factor (G-CSF) precluding subsequent autologous HSC transplantation. Plerixafor, a specific
antagonist of the chemokine receptor CXCR4, can rescue some but not all patients who failed to mobilize with G-CSF alone. These
refractory poor mobilizers cannot currently benefit from autologous transplantation. To discover alternative targetable pathways to
enhance HSC mobilization, we studied the role of hypoxia-inducible factor-1α (HIF-1α) and the effect of HIF-1α pharmacological
stabilization on HSC mobilization in mice. We demonstrate in mice with HSC-specific conditional deletion of the Hif1a gene that the
oxygen-labile transcription factor HIF-1α is essential for HSC mobilization in response to G-CSF and Plerixafor. Conversely,
pharmacological stabilization of HIF-1α with the 4-prolyl hydroxylase inhibitor FG-4497 synergizes with G-CSF and Plerixafor
increasing mobilization of reconstituting HSCs 20-fold compared with G-CSF plus Plerixafor, currently the most potent mobilizing
combination used in the clinic.
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INTRODUCTION
The cytokine granulocyte colony-stimulating factor (G-CSF) is the
main agent to mobilize hematopoietic stem cells (HSCs) for
transplantation. Administered daily at doses of 10 μg/kg, G-CSF
mobilizes hematopoietic stem and progenitor cells (HSPCs) from
the bone marrow (BM) into the circulation. In most healthy
allogeneic donors, CD34+ HSPCs are robustly mobilized after
5 days of G-CSF treatment and blood aphaeresis from day 5 is
sufficient to reach the minimum threshold of 2×106 CD34+ cells/kg
body weight to ensure rapid hematopoietic reconstitution.
However in the autologous setting, 20–60% of chemotherapy-
treated patients fail to reach this minimal threshold in response to
G-CSF, precluding transplantation1 particularly in patients with
prior radiotherapy and chemotherapy.1,2 The chemotactic inter-
action between the chemokine CXCL12 and its receptor CXCR4 is
pivotal to HSPC retention within the BM3,4 and is weakened by
G-CSF treatment causing mobilization.5–7 Additional inhibition of
the CXCL12:CXCR4 interaction with specific small synthetic
inhibitors such as Plerixafor (previously called AMD3100) syner-
gistically enhances HSPC mobilization in response to G-CSF in
humans and mice.8 The synergistic effect of Plerixafor has been
confirmed in large clinical trials with multiple myeloma and non-
Hodgkin lymphoma patients eligible for autologous HSC trans-
plantation who previously failed to mobilize in response to G-CSF
alone. Plerixafor injected daily 1 h before blood aphaeresis from
day 4 of G-CSF administration enables approximately 70–80%
patients who previously failed to mobilize in response to G-CSF
alone to reach 2 × 106 CD34+ cells/kg threshold.9,10 However, the
remaining 20–30% of patients who failed to mobilize with G-CSF
alone still fail to mobilize with G-CSF and Plerixafor.9,10 It is
therefore important to further understand the mechanisms of HSC
mobilization to identify novel therapeutics to overcome mobiliza-
tion failure in a larger proportion of patients.
The hypoxia sensing pathway is activated in the BM of mice
mobilized with G-CSF.11 Extensive myeloid progenitor proliferation
in response to G-CSF is thought to enhance O2 consumption
increasing overall BM hypoxia, which in turn stabilizes the O2-
labile protein hypoxia-inducible factor-1α (HIF-1α) in mobilized
BM.11 HIF-1α is a transcription factor that regulates metabolic
adaptation and cell responses to hypoxia.12–14 Considering the
critical role of HIF-1α in regulating HSC proliferation, self-renewal




C57BL/6 mice were purchased from the Australian Resource Centre, Perth,
Australia; B6.129-Hif1atm3Rsjo/J (Hif1aflox/flox) mice from the Jackson
Laboratory (Bar Harbor, ME, USA). Scl-CreER transgenic mice expressing a
tamoxifen-inducible Cre recombinase driven by a HSC-specific Scl gene
enhancer,19 B6-Gt(ROSA)26Sortm1(EYFP)Cos/J (abbreviated as R26RYFP) with a
loxP-flanked STOP sequence preceding an enhanced yellow fluorescent
protein (YFP) reporter gene inserted into the genetrap ROSA26 locus20
were backcrossed at least 10 times in C57BL/6 background. Mouse
genotyping is described in Supplementary Methods.
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Induction of the Scl-CreER transgene with tamoxifen
Scl-CreER mice were gavaged daily with tamoxifen-free base diluted in
peanut oil containing 10% ethanol for 3 days to induce the Scl-CreER
transgene. For mobilization experiments with G-CSF, G-CSF was adminis-
tered for 3 days beginning on the final day of tamoxifen gavaging unless
otherwise stated. For mobilization experiments with Plerixafor, Plerixafor
was administered intraperitoneally 1 week following the final day of
tamoxifen induction, 1 h before harvest. Following treatments, mice were
then euthanized by cervical dislocation and BM and bones harvested.
For migration assay and CXCR4 staining, mice were harvested 1 week
following the final day of tamoxifen induction.
Mobilization
All experiments were performed on 9- to 12-week-old male mice.
Recombinant human G-CSF was injected twice daily subcutaneously at
125 μg/kg and Plerixafor (AMD3100 octohydrochloride) intraperitoneally at
10mg/kg as described.21 Tissues were harvested 1 h after Plerixafor
administration. FG-4497 was injected daily intraperitoneally at 20mg/kg.
Control mice were injected with an equivalent volume of saline. Tissues
were harvested on the morning following the last G-CSF injection, or 1 h
following Plerixafor injection.
For studies with additional 4-prolyl hydroxylase domain enzyme (PHD)
inhibitors, G-CSF was administered twice daily subcutaneously for 4
consecutive days. PHI-1 and PHI-2 were administered daily by oral gavage
at 20mg/kg for the last 3 days of the mobilization regimen.
Tissue harvesting
Mice were anesthetized with isofluorane and approximately 1ml of blood
collected into heparinized tubes by cardiac puncture before cervical dislocation.
Femoral BM was flushed and spleens dissociated between the frosted ends of
two glass slides in phosphate-buffered saline containing 2% fetal calf serum
(FCS) for further analyses. For flow-cytometry analyses, red cells were lysed
from blood samples as previously described.22 Spleens were harvested,
weighed, dissociated in 10ml phosphate-buffered saline with 2% FCS. RNA
from the endosteum was isolated from femurs as previously described.23
Western blotting
Following treatment of mice with Saline, G-CSF or FG-4497, BM cells from one
femur were flushed with 1ml of urea cell lysis buffer containing complete
protease inhibitors (Roche, Basel, Switzerland) supplemented with 200 μM
phenylmethylsulfonyl fluoride.16 Quantitative western blots with rabbit anti-
mouse HIF-1α antibody were performed using the Odyssey Infra-Red Imaging
System (Li-COR Bioscience, Lincoln, NE, USA) as described previously.11,16
Colony assays
In all, 10 μl whole blood or splenocytes from 1/1000 of a whole spleen were
seeded in 35-mm petri dishes and covered with 1ml IMDM supplemented
with 1.6% methylcellulose, 35% FCS and optimal concentrations of mouse
IL-3, IL-6 and soluble kit ligand as described previously.24 When results are
reported as proportion of mobilized cells versus whole BM content, we
considered that one femoral BM represents 5.6% of total mouse BM and that
the total volume of blood is 0.08ml per gram of body weight.25,26
Flow cytometry
Antibody staining for expression of α4 and α5 integrins, PSGL1, CXCR4,
binding of P- and E-selectins and for HSPC cell cycling are described in
Supplementary Methods.
Quantitative real-time reversed transcribed PCR
Quantitative real-time reversed transcribed PCR (qRT-PCR) to confirm Hif1a
gene deletion in HSPC and measure Cxcr4, Cxcr7 and Cxcl12 mRNA is
described in Supplementary Methods.
Competitive repopulation assays
The content of mobilized blood samples in competitive repopulating HSC
was determined in competitive repopulation assays as previously
described.22,24 Briefly, lethally irradiated recipient congenic B6.SJL
CD45.1+ female mice were transplanted with 200 000 competitive whole
BM cells from untreated B6.SJL CD45.1+ mixed with 20 μl blood aliquots
from 6 pooled mobilized CD45.2+ C57BL/6 donor mice. CD45.2/CD45.1
chimerism was measured in blood at 8, 12 and 16 weeks post transplant in
myeloid, B and T lineages by flow cytometry. Content in repopulating units
was calculated as previously described.21,27
Migration assays
Five million whole BM cells from SclCreER R26RYFP/YFP Hif1aWT/WT or
SclCreER R26RYFP/YFP Hif1afl/fl mice were plated in each 5 μM pore transwell
inserts (Corning, Cambridge, MA, USA) in IMDM supplemented with 10%
FCS in duplicate. CXCL12 was added to wells at a concentration of 250 ng/ml.
After 4 h at 37 °C, the percentage of YFP+ and YFP− Lin−Sca1+Kit+ cells that
had transmigrated to the lower chamber was determined by flow
cytometry after addition of 1000 fluorescent counting beads (Trucount
tubes BD, Franklin Lakes, NJ, USA) in both insert and input cells. For
chemotaxis assays with BM cells from wild-type mice treated with FG-4497,
assays were set up as described above except that 40 μM FG-4497 was
added in both top and bottom chambers containing BM cells from
FG-4497-treated mice, whereas an equivalent volume of DMSO (0.2% final)
was added in both chambers containing BM cells from saline-treated mice.
Statistical analyses
Differences between treatment groups were calculated using a two-tailed
t-test, paired t-test, ANOVA with Bonferroni correction or non-parametric
Mann–Whitney test or Dunn's multiple comparison test depending on
distribution normality. A value of Po0.05 was considered as significant.
Data are presented as mean± standard deviation.
RESULTS
Hif1a gene deletion in HSPCs impairs their mobilization
in response to G-CSF
To test the hypothesis that HIF-1α has an important role in HSC
mobilization, we established a mutant mouse strain in which both
Hif1a gene alleles are specifically deleted and YFP reporter
induced in a Cre-dependent manner20 in HSCs following
treatment with tamoxifen (Figure 1a).19 Measurements of the
Cre-induced YFP reporter by flow cytometry showed that a 3-day
tamoxifen treatment of SclCreER R26RYFP/YFP Hif1afl/fl mice caused
Cre activation in 30 ± 9% of Lin−Sca1+Kit+CD48−CD150+ HSCs,
10 ± 5% of Lin−Sca1+Kit+ HSPCs but was virtually undetected in
Lin−Sca1−Kit+ myeloid/lymphoid progenitors or lineage-positive
cells (Figures 1b and d). Therefore, a short tamoxifen treatment
activates CreER specifically in the HSC compartment in these mice.
To confirm Hif1a gene deletion, a primer pair was designed with
the forward primer in the floxed exon 2 and the reverse primer in
exon 3 of the Hif1a gene to quantify by qRT-PCR intact Hif1a
mRNA. Lin−Sca1−Kit+ YFP+ HSPCs and Lin−Sca1+Kit+CD48−CD150+
HSCs were sorted 4 days after the end of the 3-day induction with
tamoxifen and assessed for Hif1a mRNA content by qRT-PCR.
Intact Hif1a mRNA was significantly reduced in HSCs and HSPCs
from SclCreER R26RYFP/YFP Hif1afl/fl mice compared with SclCreER
R26RYFP/YFP Hif1aWT/WT mice (Supplementary Figure S1). We also
plated sorted Lin−Sca1−Kit+ YFP+ HSPCs in colony assays in
methylcellulose. After 9 days of culture, individual colonies were
picked and RNA extracted. Intact Hif1a mRNA was undetectable in
colonies from SclCreER R26RYFP/YFP Hif1afl/fl mice (Figure 1e).
Together, these results demonstrate efficient deletion of the Hif1a
gene in HSCs following tamoxifen gavage in SclCreER R26RYFP/YFP
Hif1afl/fl mice.
SclCreER R26RYFP/YFP Hif1afl/fl mice and control SclCreER R26RYFP/YFP
Hif1aWT/WT mice were induced with tamoxifen for 3 days and
then G-CSF for 3 days from the last day of tamoxifen induction
(Figure 1b). Deletion of Hif1a gene in HSPCs significantly reduced
G-CSF-induced mobilization of colony-forming cells (CFCs) to the
blood (Figure 1f), and phenotypic HSPCs and HSCs to the blood
and spleen of SclCreER R26RYFP/YFP Hif1afl/fl mice compared with
control SclCreER R26RYFP/YFP Hif1aWT/WT mice (Figures 1g and h).
Decreased HSC mobilization following Hif1a deletion was not due
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to decreased number of HSCs in the BM as SclCreER R26RYFP/YFP
Hif1afl/fl and control SclCreER R26RYFP/YFP Hif1aWT/WT mice had
similar numbers of HSCs per femur following deletion with
tamoxifen and G-CSF treatment and similar total number of HSCs
following summation of HSC numbers in total skeletal BM, blood
and spleen (Supplementary Figure S2). As Hif1a was deleted from
approximately 30% of HSCs in SclCreER R26RYFP/YFP Hif1afl/fl mice
treated with tamoxifen and G-CSF, we took advantage of this mosaic
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deletion to calculate within each individual mouse the proportion of
YFP− (Hif1afl gene intact, not deleted) and YFP+ (Hif1a deleted)
Lin−Sca1+Kit+ HSPCs mobilized to blood or spleen compared with
those remaining within the BM. Within each individual mouse, the
proportion of YFP+ Hif1a-deleted HSPCs that left the BM to mobilize
into blood or spleen was 12-fold and 5-fold lower, respectively, than
the proportion of YFP- Hif1a-intact HSPCs mobilized to blood and
spleen (Figures 1i and j). Therefore, Hif1a gene deletion in HSPCs
impairs their mobilization in response to G-CSF.
Hif1a deletion impairs mobilization induced by CXCR4 blockade
We next evaluated the effect of Hif1a gene deletion on
mobilization in response to the CXCR4 antagonist Plerixafor.
SclCreER R26RYFP/YFP Hif1afl/fl mice and control SclCreER R26RYFP/YFP
Hif1aWT/WT mice were induced with tamoxifen for 3 days and
then with a single dose of Plerixafor 1 week following the last day
of tamoxifen induction. Deletion of Hif1a gene significantly
reduced Plerixafor-induced mobilization of CFCs to the blood
(Figure 2a). We calculated within each individual mouse the
proportion of YFP− (Hif1a gene intact) and YFP+ (Hif1a deleted)
Lin−Sca1+Kit+ HSPCs mobilized to blood versus the number of
Hif1a-intact or Hif1a-deleted HSPCs remaining within the BM.
Within each individual mouse, the proportion of YFP+ Hif1a-
deleted HSPCs that mobilized into blood or spleen significantly
reduced compared with the proportion of YFP+ Hif1a-intact HSPCs
that mobilized to the blood (Figure 2b). This demonstrates that
Hif1a gene deletion in HSPCs severely impairs mobilization in
response to CXCR4 blockade.
To investigate whether Hif1a gene deletion disrupts the CXCR4/
CXCL12 chemotactic signaling pathway, we performed a transmi-
gration assay toward CXCL12. Whole BM cells were isolated from
SclCreER R26RYFP/YFP Hif1afl/fl mice and SclCreER R26RYFP/YFP
Hif1aWT/WT mice induced with tamoxifen for 3 days, and deposited
into transwells with 250 ng/ml CXCL12 in the bottom chamber.
We calculated within each individual SclCreER R26RYFP/YFP Hif1afl/fl
mouse, the proportion of YFP− (Hif1a gene not deleted) and YFP+
(Hif1a deleted) Lin−Sca1+Kit+ HSPCs that migrated toward CXCL12.
YFP+ (Hif1a deleted) HSPCs exhibited significantly reduced
migration toward CXCL12 compared with YFP- (Hif1a gene intact)
HSPCs (Figure 2c). In control SclCreER R26RYFP/YFP Hif1aWT/WT mice,
migration of YFP+ and YFP− HSPCs in response to CXCL12 was not
significantly different (Figure 2d), suggesting that impaired
migration toward CXCL12 was specifically due to Hif1a deletion.
As cell surface expression of CXCR4 is very low, we quantified
Cxcr4 mRNA by qRT-PCR on Lin−Sca1−Kit+ YFP+ HSPCs from
SclCreER R26RYFP/YFP Hif1afl/fl mice and SclCreER R26RYFP/YFP
Hif1aWT/WT mice 4 days after a 3-day induction with tamoxifen.
Cxcr4 expression was however not altered by Hif1a deletion. We also
tested for the expression of CXCR7, a related chemokine receptor
previously shown to bind CXCL12 and dimerize and co-signal with
CXCR4 on human CD34+ HSPCs.28,29 Using an anti-CXCR7 mono-
clonal antibody cross-reactive for human and mouse CXCR7, as well
as TaqMan primer probe set for mouse Cxcr7 mRNA, we could not
detect CXCR7 protein or mRNA in mouse BM HSPCs (data not
shown), in agreement with expression array reported on www.
biogps.org showing lack of expression in adult mouse HSCs.
FG-4497 synergizes with G-CSF to enhance mobilization
As HIF-1α is critical to HSPC mobilization in response to G-CSF or
Plerixafor (Figures 1 and 2), we tested whether further stabilization
of the HIF-1α protein, which is O2-labile, may enhance mobiliza-
tion in response to G-CSF and Plerixafor. We injected wild-type
mice with the PHD inhibitor FG-4497 to block HIF-1α proline
hydroxylation in oxidative conditions and downstream recruit-
ment of the ubiquitin ligase VHL and O2-dependant proteasomal
degradation of HIF-1α.16,30,31 HIF-1α protein was very low in BM
cell lysates from saline-injected animals and significantly increased
following G-CSF treatment (Figure 3a) consistent with our previous
findings.11 However, treatment with FG-4497 or the combination
of FG-4497 with G-CSF further increased HIF-1α protein levels
compared with G-CSF alone (Figure 3a).
We next treated C57BL/6 mice with G-CSF twice daily for
1–3 days together with the PHD inhibitor FG-4497 daily for
the 3 days before tissue harvest. FG-4497 treatment on top of
the 3 day G-CSF treatment increased CFCs mobilized per ml blood
2.5-fold following 2 days of G-CSF, and 6-fold the number of CFCs
mobilized per spleen compared with G-CSF treatment alone
(Figure 3b). Of note, 3-day treatment with FG-4497 alone without
G-CSF did not induce CFC mobilization into the blood compared
with control mice injected with vehicle (not shown).
To evaluate the effect of FG-4497 treatment duration, FG-4497
was administered for 1–3 days and G-CSF for the last 2 days before
tissue sampling (Figure 3c). CFC mobilization into blood and
spleen in response to 2 days of G-CSF progressively increased with
the duration of FG-4497 treatment.
Of note FG-4497 did not enhance mobilization of Lin−Sca1+Kit+
HSPCs to blood and spleen in SclCreER R26RYFP/YFP Hif1afl/fl mice
treated with tamoxifen whereas it further enhanced mobilization
of HSPCs in control SclCreER R26RYFP/YFP Hif1aWT/WT mice
(Supplementary Figure S3). Therefore, the enhancing effect of
FG-4497 on HSPC mobilization is specifically mediated by HIF-1α
protein.
FG-4497 synergizes with Plerixafor to enhance CFC mobilization
Since mobilization with Plerixafor peaks 1 h post injection,8 this
time point was used together with daily administration of FG-4497
for 1–3 days before killing (Figure 3d). CFCs mobilization into
Figure 1. Deletion of Hif1a gene in HSPCs compromises HSPC mobilization in response to G-CSF. (a) Schematic representation of the
tamoxifen-inducible Cre-dependant Hif1a deletion and YFP induction. Mice were mated to obtain two floxed Hif1a alleles (Hif1afl/fl), with a Cre-
inducible YFP reporter knocked in the Rosa26 gene trap locus (R26RYFP) and a tamoxifen-inducible Cre recombinase (CreER fusion protein)
driven by the HSC-specific 6E5 enhancer fragment and promoter of the Scl gene (SclCreER). Tamoxifen specifically activates CreER in HSCs and
consequently deletes the two Hif1a alleles and activates YFP expression. (b) Time course of CreER activation in HSPCs and mobilization with
G-CSF. Tamoxifen was administered daily for 3 days and then mice were mobilized for 3 days with G-CSF twice daily. (c, d) Proportion of
Lin−Sca1+Kit+ CD48− CD150+ HSCs, Lin−Sca1+Kit+ HSPCs, Lin−Sca1−Kit+ myeloid progenitors and Lin+ leukocytes in which YFP is induced by
CreER following a 3-day tamoxifen treatment in SclCreER R26RYFP/YFP Hif1afl/fl mice. (e) qRT-PCR showing levels of Hif1amRNA in Lin− Sca1+ Kit+
YFP+ HSPCs sorted from the BM of SclCreER R26RYFP/YFP Hif1afl/fl (Hif1afl/fl) mice or SclCreER R26RYFP/YFP Hif1aWT/WT (Hif1aWT/WT) mice and grown
for 9 days in a colony assay. Results are relative to β-actin mRNA, each dot represents a separate mouse. (f) Number of CFCs mobilized into
blood in SclCreER R26RYFP/YFP Hif1afl/fl mice and control SclCreER R26RYFP/YFP Hif1aWT/WT mice. Each dot represents a separate mouse. (g, h)
Number of phenotypic Lin−Sca1+Kit+CD48−CD150+ HSCs, Lin−Sca1+Kit+ HSPCs mobilized into blood (g) and spleen (h) in SclCreER R26RYFP/YFP
Hif1afl/fl mice and control SclCreER R26RYFP/YFP Hif1aWT/WT mice. Data are mean± s.d. of seven mice per group. P-values were calculated with a
t-test. (i, j) Proportion of YFP− (Hif1afl/fl non-deleted) and YFP+ (Hif1aΔ/Δ deleted) HSCs in the blood (i) or spleen (j) over YFP− or YFP+ HSCs
remaining in the BM following a CreER induction with tamoxifen and a 3-day G-CSF treatment. Pairs of dots show results for YFP− and YFP+
HSC within the same SclCreER R26RYFP/YFP Hif1afl/fl mouse. P-values were calculated with a paired t-test. Symbols for significance levels are
*Po0.05; **0.001oPo0.01; ***Po0.001.
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blood in response to Plerixafor was significantly increased by a
2–3 day treatment with FG-4497 treatment demonstrating
synergy between CXCR4 inhibition and PHD inhibition. As
mobilization in response to Plerixafor is very rapid, there was no
significant mobilization of HSPCs to the spleen 1 h following
Plerixafor treatment with or without FG-4497.
FG4497 does not increase mobilization by altering HSPC cycling
or survival
As we have previously reported that a 7-day FG-4497 treatment
inhibits HSPC proliferation in vivo in mice in steady state,16 we first
evaluated 5-bromodeoxyuridine (BrdU) incorporation over 3 days
and Ki67 antigen expression in BM HSPC from mice treated with
Figure 2. Deletion of Hif1a gene in HSPCs disrupts the CXCR4 signaling pathway. (a) Number of CFC per mL blood following a CreER induction
with tamoxifen and a 1 h treatment with Plerixafor. Each dot represents a mouse. (b) Proportion of YFP− (Hif1afl/fl non-deleted) and YFP+
(Hif1aΔ/Δ deleted) Lin−Sca1+Kit+CD48-CD150+ HSCs in the blood over YFP− or YFP+ HSCs remaining in the BM following a CreER induction with
tamoxifen and a 1-h treatment with Plerixafor. Each pair of dots shows results from YFP− and YFP+ HSCs within the same SclCreER R26RYFP/YFP
Hif1afl/fl mouse. Significance was calculated with a paired t-test. (c, d) Proportion of YFP− and YFP+ LSK HSPCs migrated toward CXCL12 as
percentage of input YFP− or YFP+ HSPCs. Pairs of dots show results for YFP− and YFP+ HSCs within each single SclCreER R26RYFP/YFP Hif1afl/fl
mouse (c) or control SclCreER R26RYFP/YFP Hif1awt/wt mouse (d). Significance were calculated with a paired t-test. (e) Cxcr4 mRNA expression
levels in Lin−Sca1+Kit+ YFP+ HSPCs sorted from the BM of SclCreER R26RYFP/YFP Hif1afl/fl (Hif1afl/fl) mice or SclCreER R26RYFP/YFP Hif1aWT/WT
(Hif1aWT/WT) mice. Data are relative to β-actin mRNA. Data are mean± s.d. of 4–5 mice per group. Symbols for significance levels are
**0.001oPo0.01; ***Po0.001.
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Figure 3. Effect of FG-4497 on HIF-1α protein and CFC mobilization. (a) BM cell lysates from mice treated with saline, FG-4497 for 3 days (F),
G-CSF for 2 days (G) or both (GF) were western blotted for HIF-1α and β-actin. Each lane represents a different mouse. Histograms represent
means± s.d. of three mice per treatment group. (b) Number of CFCs per ml blood and per spleen when mice were injected twice daily with
G-CSF for indicated numbers of days and injected daily with FG-4497 for the last 3 days prior harvest. Significance levels are for each time
point between groups treated with G-CSF alone or with G-CSF plus FG-4497. (c) Number of CFCs per ml blood and per spleen when mice were
injected daily with FG-4497 for the indicated numbers of days and injected twice daily with G-CSF for 2 days prior harvest. Significance levels
are relative to the group treated with G-CSF without FG-4497. (d) Number of CFCs per ml blood and per spleen when mice were injected daily
with FG-4497 for indicated numbers of days and injected with Plerixafor for 1 h prior harvest. Significance levels are relative to the group
treated with Plerixafor without FG-4497. Data are mean± s.d. of six mice per condition. Symbols for significance levels are *Po0.05;
**0.001oPo0.01; ***Po0.001.
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saline, FG-4497 for 3 days, G-CSF for 2 days or G-CSF for 2 days
together with FG-4497 for 3 days (Supplementary Figure S4A).
A 3-day treatment with FG-4497 was not sufficiently long to
significantly increase the proportion of Lin−Sca1+Kit+ HSPCs or
Lin−Sca1+Kit+CD48-CD150+ HSCs in phase G0, or to counteract the
increased cycling caused by 2 days of G-CSF (Po0.05 for HSCs
and HSPCs in G0 in Saline vs G-CSF groups; or FG-4497 vs G-CSF
plus FG4497 groups; but P40.4 for G-CSF vs G-CSF plus FG4497
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groups). Therefore, this short FG-4497 treatment did not increase
HSPC mobilization by altering their cycling. We also measured the
effect of FG-4497 on HSPC apoptosis. In overnight cultures of BM
cells with 10 ng/ml Kit ligand, addition of 40 μM FG-4997, a
concentration that stabilizes HIF-1α in cultured HSPC,32 did not
alter the proportion of live non-apoptotic annexin V-negative,
7-aminoactinomycin D-negative HSPCs (Supplementary Figure
S4B). Finally, FG-4497 treatment alone did not alter number of
Lin−Kit+Sca1+ HSPC in the femoral BM compared with saline-
treated mice. In contrast, the combination of 2 days G-CSF with
3 days FG-4497 reduced HSPC number in the BM significantly
more than G-CSF alone treatment (Supplementary Figure S4C).
Therefore, increased mobilization with G-CSF plus FG-4497 is not
due to an increase in HSPC number in the BM. Rather, the
decrease in the number of HSPCs in the BM may reflect better
mobilization efficiency.
FG-4497 alters CXCR4 distribution and signaling in G-CSF-mobilized
mice
Mice were treated for 3 days of FG-4497 or saline, and with G-CSF
for the last 2 days before BM harvest, a time point with highest
blood mobilization difference between mice treated with G-CSF
alone or with G-CSF plus FG-4497 (Figure 3b). Cell surface
expression of CXCR4 was very low on BM Lin−Sca1−Kit+ HPCs or
Lin−Sca1+Kit+ HSPCs from mice treated with G-CSF plus FG-4497
compared with mice treated with G-CSF alone in terms of both
percentage of positive cells and fluorescence intensity for CXCR4
(Figure 4a). As an important pool of CXCR4 protein remains
intracellular in stem and progenitor cells,33 we performed
intracellular staining on fixed and permeabilized BM cells. Indeed
a much higher proportion of Lin−Sca1−Kit+ HPCs or Lin−Sca1+Kit+
HSPCs stained positively for intracellular CXCR4. Treatment with
FG-4497 significantly reduced CXCR4 intracellular staining with or
without additional G-CSF treatment in terms of both percentage
of positive cells and fluorescence intensity for CXCR4 (Figure 4b).
qRT-PCR on Lin− Sca1+ Kit+ HSPCs sorted from the BM of these
treated mice showed that FG-4497 treatment or G-CSF treatment
did not significantly alter Cxcr4 mRNA expression by one-way
ANOVA (Figure 4c). Taken together, this suggests that FG-4497
alters CXCR4 internalization or intracellular trafficking in HSPCs.
BM cells from these mice were also tested in a chemotaxis assay
in the presence of 100 ng/ml CXCL12 in the bottom chamber. BM
Lin−Kit+Sca1+ HSPC from mice treated with G-CSF plus FG-4497
migrated less toward CXCL12 compared with HSPC isolated from
mice treated with G-CSF alone (Figure 4d), suggesting that
FG-4497 treatment decreases CXCR4 signaling in HSPC from
mobilized mice.
When repeated in mice not treated with G-CSF, 3-day FG-4497
treatment did not increase CXCR4 expression on HSPC isolated
from mice in steady state. Likewise, the FG-4497 treatment did not
alter transmigration toward CXCL12 (not shown). This may explain
why FG-4497 alone does not mobilize HSPC in vivo.
We extracted RNA from endosteal cells from the femurs of mice
treated with saline, FG-4497 alone, G-CSF alone or combination of
G-CSF plus FG-4497. qRT-PCR revealed that Cxcl12 mRNA was
further decreased in the G-CSF plus FG-4497 combination group
compared with G-CSF alone, suggesting that FG-4497 further
reduce expression of CXCL12 by BM stromal cells in response to
G-CSF (Figure 4e). Interestingly, in the absence of G-CSF, treatment
with FG-4497 alone did not alter Cxcl12 mRNA levels.
We also tested whether pharmacological stabilization of HIF-1α
could alter adhesive interactions of HSPCs mediated by endothe-
lial selectins, α4 and α5 integrins which are important to retain
HSPC within the BM.34–36 FG-4497 did not reduce binding of
recombinant mouse E-selectin or P-selectin-IgG1 fusion proteins
to BM HSPCs, although G-CSF treatment significantly reduced
P-selectin binding (Supplementary Figure S5). Cell surface expres-
sion of PSGL1, α4 and α5 integrins on BM HSPCs was not altered
by in vivo treatments with FG-4497 (Supplementary Figure S5).
Other PHD inhibitors enhance HSPC mobilization
To further document the potentiating effect of PHD inhibitors on
HSPC mobilization, C57BL/6 mice were treated with two additional
novel PHD inhibitors (PHI-1 and PHI-2) from chemically distinct
structural classes (US patents number 7 696 223 and 7 928 120).
Although representing different chemical series, FG-4497, PHI-1 and
PHI-2 are all structural mimetics of the PHD substrate 2-oxoglutarate
and inhibitors of the HIF PHD enzymes.37 Combinations of either
PHI-1 or PHI-2 with G-CSF increased CFCs, Lin−Sca1+Kit+ HSPCs and
Lin−Sca1+Kit+CD48-CD150+ HSCs mobilization into blood compared
with G-CSF alone treated animals (Figure 5).
PHD inhibition synergizes with the combination of G-CSF
and Plerixafor
Since FG-4497 synergized with either G-CSF or Plerixafor, we
tested whether FG-4497 could further enhance the mobilizing
effect of the combination of G-CSF with Plerixafor. Mice were
treated with G-CSF for 2 or 4 days, with or without Plerixafor 1 h
before harvest or with or without FG-4497 for 3 days prior harvest
(Figure 6a). The combination of G-CSF plus Plerixafor plus FG-4497
was much more potent at mobilizing CFCs, phenotypic HSPCs and
HSCs to blood and spleen than the dual combination of G-CSF and
Plerixafor (Figures 6b and d). At day 4 of mobilization, the
numbers of CFCs, phenotypic HSPCs and HSCs mobilized into
blood were 2.4-fold, 5.7-fold and 5.7-fold higher with G-CSF,
Plerixafor and FG-4497 than with G-CSF plus Plerixafor without
FG-4497. Of note, the dual combination G-CSF plus FG-4497
mobilized CFCs, HSPCs and HSCs into blood better than the dual
combination of G-CSF plus Plerixafor although mobilization to the
spleen was equivalent with these two regimens.
Figure 4. Effect of FG-4497 and G-CSF treatment on CXCR4 expression and cell migration. (a) Cell surface expression of CXCR4 on
Lin−Sca1−Kit+ BM HPCs (LKS-) and Lin−Sca1+Kit+ HSPCs (LKS+) from mice treated for 2 days with saline (S), or with FG-3347 for 3 days (F), or
with G-CSF for 2 days (G), or the combination of FG-4497 and G-CSF treatments (G+F). Flow-cytometry profiles on the left are overlays of
CXCR4 protein expression with isotype matched control of CXCR4 antibody in shaded area, HSPCs from mice treated with G-CSF alone in blue,
or with combination of G-CSF plus FG-4497 in red. The gray area represents fluorescence with APC-conjugated rat IgG2b Control. The middle
and right plots represent cell surface CXCR4 mean fluorescence intensity and the proportion cells that are positive for CXCR4 respectively.
Each dot represents an individual mouse. The bars are average for each group. (b) Intracellular staining for CXCR4 on Lin−Sca1−Kit+ BM HPCs
(LKS−) and Lin−Sca1+Kit+ HSPCs (LKS+) from mice treated for 2 days with saline (S), or with FG-3347 for 3 days (F), or with G-CSF for 2 days (G),
or the combination of FG-4497 and G-CSF treatments (G+F) as described in (a). (c) qRT-PCR for Cxcr4mRNA on Lin− Sca1+ Kit+ cells sorted from
the BM of mice treated with saline (S), FG-4497 (F), G-CSF (G) or combination of FG-4497 and G-CSF treatments (G+F). (d) Transwell migration
of Lin−Sca1+Kit+ BM cells from mice treated for 2 days with G-CSF (black line and dots), or with FG-3347 for 3 days and G-CSF for the last
2 days, against 100 ng/ml CXCL12 in the bottom chamber. Each dot represents an individual mouse. The bars are average± s.d. Significance
levels were calculated with Mann–Whitney test. (e) Cxcl12 mRNA expression relative to β-actin in endosteal cells from mice treated with saline,
FG-4497 for 3 days, G-CSF or 2 days or with FG-3347 for 3 days and G-CSF for the last 2 days. The chart shows median, 95% confidence
intervals, maximum and minimum values from eight separate mice per treatment group. Significance levels were calculated with Dunn's test.
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This synergistic increase in HSC mobilization was further
confirmed in long-term competitive repopulation assays following
transplantation of 20 μl mobilized blood from CD45.2+ C57BL/6
mice in competition with 2 × 105 BM cells from CD45.1+ B6.SJL
congenic donors. CD45.2+ donor versus CD45.1+ competitor
chimerism 16 weeks post transplantation confirmed that the tri-
combination G-CSF plus Plerixafor plus FG-4497 mobilized
competitive repopulating HSCs more than the dual combination
G-CSF plus Plerixafor at both time points of G-CSF treatment
Po0.01 (Figures 7a and b). Reconstitution with mobilized blood
was significantly higher in all blood lineages (B, T and myeloid
cells) (Figure 7c) with G-CSF plus Plerixafor plus FG-4497,
mobilizing repopulating units 1.8-fold more at day 2, and 20-
fold more at day 4 than the dual combination G-CSF plus
Plerixafor (Figures 7a and b).
Long-term competitive transplantation assays also confirmed
that G-CSF plus FG-4497 mobilized repopulating units 16-fold
more than the combination of G-CSF plus Plerixafor at day 4 with
higher multi-lineage chimerism.
DISCUSSION
Using conditional deletion of the Hif1a gene specifically in HSCs
and immature HSPCs, we demonstrate that HIF-1α is required for
Figure 5. Two orally available PHD inhibitors enhance HSPC mobilization induced by G-CSF. C57BL/6 mice were injected subcutaneously twice
daily with human G-CSF (125 μg/kg) for 4 consecutive days and gavaged once daily with vehicle (G), 20 mg/kg PHI-1(G+PHI1) or PHI-2
(G+PHI2) during the last 3 days of G-CSF injection. Mice were killed the next morning following that last G-CSF injection and numbers of CFCs,
Lin−Sca1+ Kit+ (LSK) HSPCs and Lin−Sca1+Kit+CD48-CD150+ (LSK48- 150+) HSCs per ml of blood and per spleen measured. Data are mean± SD
of six mice per group. P-values are relative to G-CSF treated group and were calculated with a Student’s t-test. *Po0.05; **0.001oPo0.01;
***Po0.001.
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Figure 6. Synergistic effect of FG-4497 with G-CSF and Plerixafor. (a) Experimental scheme: Cohorts of mice were injected twice daily with
G-CSF alone for 2 or 4 days (gray lines), or G-CSF for 2 or 4 days with one Plerixafor injection 1 h before tissue harvest (black lines). The effect of
FG-4497 was tested by injecting mice daily with FG-4497 to mice injected twice daily with G-CSF for the last 2 or 4 days before tissue harvest
(green lines). Alternatively FG-4497 was injected daily to mice injected twice daily with G-CSF for the last 2 or 4 days, and Plerixafor 1 h before
tissue harvest (red lines). (b–d) Number of CFCs (b), Lin−Sca1+Kit+ HSPCs (c) and Lin−Sca1+Kit+CD48-CD150+ HSCs (d) per ml of blood or per
spleen following treatments with combinations of G-CSF, Plerixafor and FG-4497 as in (a). Data are mean± s.d. of six mice per time point per
treatment group. For statistical analyses, we compared (a) G-CSF alone group (gray line) to G-CSF with FG-4497 group (green line) and (b)
G-CSF+Plerixafor group (black line) to G-CSF+Plerixafor+FG-4497 group (red line). Significant differences between treatment groups were
calculated by one-way ANOVA with Bonferroni correction for multiple comparisons. Significant differences are indicated by brackets with the
following symbols: *Po0.05; **0.001oPo0.01; ***Po0.001.
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HSPC mobilization in response to G-CSF or Plerixafor. More
relevant to the clinic, we also demonstrate that pharmacological
stabilization of HIF-1α protein with small synthetic PHD inhibitors
synergizes with both G-CSF and Plerixafor to increase HSC
mobilization into the blood. Indeed, additional stabilization of
HIF-1α protein with the PHD inhibitor FG-4497 increased 20-fold
the long-term repopulation potential of blood mobilized with
G-CSF plus Plerixafor, currently the best available therapeutic
combination to mobilize HSCs in autologous patients that
previously failed to mobilize with G-CSF alone. This was not due
to an off-target effect of FG-4497 as this drug did not enhance
mobilization of HSPCs conditionally deleted for the Hif1a gene.
Furthermore, other PHD inhibitors from different structural classes
also enhanced HSPC mobilization similar to FG-4497. The
synergistic effect of PHD inhibitors on HSC mobilization and
engraftment upon transplantation is consistent with the recent
finding that a short exposure ex vivo of HSPCs to dimethyl
prostaglandin E2 stabilizes HIF-1α and subsequently doubles HSC
Figure 7. FG-4497 synergizes with G-CSF and Plerixafor to enhance mobilization of competitive repopulating HSCs. (a) CD45.2+ chimerism
after transplantation of blood mobilized for 2 days with G-CSF, Plerixafor and FG-4497. CD45.2+ donors were mobilized with G-CSF alone for
2 days (G2), or G-CSF in combination with Plerixafor (G2P) or FG-4497 (G2F) or with both Plerixafor and FG-4497 (G2PF ) following the same
schedule as in Figure 5a. 20 μl blood was transplanted in lethally irradiated recipients together with 200 000 competitive BM cells from
CD45.1+ mice. Proportion of blood CD45.2+ leukocytes at 16 weeks post transplantation and number of repopulating units per ml of
mobilized blood calculated from donor chimerism at 16 weeks post transplantation. (b) CD45.2+ chimerism after transplantation of blood
mobilized for 4 days with G-CSF, Plerixafor and FG-4497. CD45.2+ donors were mobilized with G-CSF alone for 4 days (G4), or G-CSF in
combination with Plerixafor (G4P) or FG-4497 (G4F) or with both Plerixafor and FG-4497 (G4PF ) following the same schedule as in Figure 5a.
(c) CD45.2+ donor contribution was measured in blood 16 weeks post transplantation in total CD11b+ myeloid cells, B220+ B cells and CD3+
T cells by flow cytometry. Each dot is a result from one recipient mouse, bars are average, dotted lines represent 0.5% CD45.2+ threshold
above which chimerism was considered as positive. *Po0.05; **0.001oPo0.01; ***Po0.001 using a non-parametric Mann–Whitney test.
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homing to the BM and long-term engraftment.18 Therefore, in vivo
treatment with PHD inhibitors may have the double advantage of
(1) quantitatively increasing the number of HSCs mobilized into
the blood and (2) increasing their subsequent homing and
engraftment efficiency once transplanted.
Mechanistically, we show that Hif1a gene deletion inhibited
HSPC mobilization in response to the CXCR4 inhibitor Plerixafor,
and reduced their migration toward CXCL12 gradient without
altering Cxcr4 mRNA expression. However, due to the extremely
low levels of CXCR4 protein at the surface of mouse HSPCs in the
BM, we could not detect significant changes in CXCR4 protein at
the surface of HSPCs following Hif1a gene deletion. Because of this
we could not detect changes in cell surface CXCR4 protein on
HPSCs from mice treated with FG-4497. However, treatment of
wild-type mice with FG-4497 alone or in combination with G-CSF,
which further stabilizes HIF-1α protein, significantly reduced
intracellular CXCR4 protein in HSPCs compared with mice treated
with saline or with G-CSF alone. However, FG-4497 treatment did
not alter Cxcr4 mRNA expression in HSPCs. This is consistent with
previous findings showing that deletion of Hif1a gene in all
hematopoietic cells and in stromal cells in Mx1-Cre Hif1afl/fl mice
did not alter Cxcr4 mRNA or CXCR4 protein surface expression on
HSPCs.17 In addition, we found that in vitro chemotaxis of BM
HSPCs isolated from mice treated with G-CSF plus FG-4497 was
also decreased compared with HSPCs from mice treated with
G-CSF alone. This is in contrast with a recent report that ex vivo
treatment of BM HSPCs with dimethyl prostaglandin E2, which
also increases HIF-1α protein, enhanced HSPC transmigration
toward CXCL12.18 A possible reason for this discrepancy is that
dimethyl prostaglandin E2 was used in ex vivo once HSCs removed
from their physiological niches while in our experiments, FG-4497
was administered in vivo. Also, dimethyl prostaglandin E2 is likely
to activate via its four receptors EP1-4 many other pathways in
addition to HIF-1α.38 Finally, we found that the combination of
FG-4497 plus G-CSF further exacerbated the reduction of Cxcl12
mRNA expression in the BM stroma in response to G-CSF.
Therefore, the effect of FG-4497 is likely mediated in part by
perturbation of CXCR4 signaling (HSPC autonomous effect) and
CXCL12 expression (extrinsic effect) in G-CSF-treated mice, which
may ultimately lead to enhanced mobilization. In summary, our
data suggest that in G-CSF-treated mice, HIF-1α stabilization with
FG-4497 qualitatively alters or quantitatively decreases CXCR4
chemotactic signaling. However, as HIF-1α activates the transcrip-
tion of hundreds of genes,14,39 it is likely that HIF-1α enhances
HSPC mobilization via several parallel mechanisms. Therefore, the
effect of HIF-1α stabilization on HSPC mobilization is likely to be
complex resulting from both HSC autonomous mechanisms and
stroma mediated-mechanisms. Ongoing studies in our laboratory
to profile the transcriptome of HSPCs from mice treated with
FG-4497 will provide insights about its additional mechanisms of
action on HSPC mobilization.
If corroborated in humans, then our current study suggests that
PHD inhibitors such as FG-4497 could advantageously replace
Plerixafor or be added to G-CSF and Plerixafor to form an even
more potent mobilizing cocktail that could further reduce the
numbers of patients who fail to mobilize sufficiently to proceed
with autologous HSC transplantation. Indeed, PHD inhibitors are
safe in humans and currently tested in several clinical trials to treat
anemia associated with chronic renal diseases.37 Therefore, PHD
inhibitors may have the potential to (1) reduce the high cost of
remobilization40,41 and make it more accessible to patients
requiring autologous HSC transplant and (2) be used upfront
with G-CSF to increase the number of HSCs harvested in both the
allogeneic and autologous setting as transplantation of higher
doses of HSCs (45 × 106 CD34+ cells/kg) further reduce the period
of cytopenia, risks of potentially fatal febrile neutropenia, and
transfusion costs associated with prolonged anemia and
thrombocytopenia.
In conclusion, our work demonstrates that HIF-1α is necessary
to HSPC mobilization in mice and opens the perspective of using
PHD inhibitors in combination with G-CSF to boost HSC
mobilization for transplantation in humans.
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